Dipyridamole

證據等級: L5

預測適應症: 10 個

Dipyridamole: From Thromboembolism Prevention to Prinzmetal Angina

One-Sentence Summary

Dipyridamole is a well-established antiplatelet and coronary vasodilator drug used globally for thromboembolic prevention, particularly in combination with aspirin or warfarin, though it has no registered products in the Philippines. The TxGNN model ranks Prinzmetal Angina as its top predicted new indication (score: 99.99%), with no clinical trials and 15 publications currently associated with this direction. ⚠️ Critical Safety Note: Published literature indicates dipyridamole is used clinically as a pharmacological provocateur to trigger coronary vasospasm for diagnostic purposes — suggesting a potential contraindication rather than a therapeutic opportunity in this condition.

Quick Overview

Item	Content
Original Indication	Thromboembolism prevention / Antiplatelet therapy (no Philippines regulatory data available)
Predicted New Indication	Prinzmetal Angina
TxGNN Prediction Score	99.99%
Evidence Level	L4
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this Evidence Pack. Based on known pharmacology, Dipyridamole inhibits phosphodiesterase enzymes (raising platelet cAMP and vascular smooth muscle cGMP) and blocks adenosine reuptake by red blood cells — resulting in coronary vasodilation and inhibition of platelet aggregation. The vasodilatory component appears mechanistically relevant to Prinzmetal angina, a condition driven by episodic coronary artery spasm, because relaxing coronary vascular tone could theoretically suppress spasm.

However, clinical evidence reveals a far more complicated relationship. Dipyridamole induces maximal vasodilation in normal coronary segments, while vessels prone to spasm respond differently — creating a relative underperfusion through the coronary steal phenomenon. This is precisely why dipyridamole is used as a pharmacological stress test agent to provoke ischemia for diagnostic purposes, not to treat it. A 1988 mechanistic case series (PMID 3421166) explicitly documented that dipyridamole stress testing followed by aminophylline reversal can actively trigger coronary vasospasm in variant angina patients. The earliest clinical report (PMID 633593, 1978) further confirms that dipyridamole not only failed to suppress angina attacks in Prinzmetal patients but tended to aggravate them.

In summary, TxGNN has detected a real biological association between dipyridamole and Prinzmetal angina, but the direction of effect is provocation, not treatment. The model reflects connectivity in the knowledge graph without distinguishing causality or clinical intent. This constitutes a critical safety signal that warrants a Hold decision.

Clinical Trial Evidence

Currently no related clinical trials registered for Dipyridamole in Prinzmetal Angina.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
633593	1978	Early Clinical Report	Japanese Circulation Journal	In 26 patients with angina at rest (including Prinzmetal’s variant), dipyridamole 50 mg not only failed to suppress attacks but tended to aggravate them in all Prinzmetal cases
3421166	1988	Mechanistic Case Series	American Journal of Cardiology	⚠️ Dipyridamole stress testing followed by aminophylline reversal triggers coronary vasospasm in variant angina via sudden withdrawal of vasodilation — confirms use as a provocateur, not a treatment
3190956	1988	Observational	British Heart Journal	Exercise test reproducibility in 25 patients with ST elevation; dipyridamole echocardiography used as diagnostic tool to stratify vasospasm vs. fixed stenosis
8417062	1993	Echocardiography Study	Journal of the American College of Cardiology	Myocardial echodensity changes during ischemic episodes of varying severity and duration induced by dipyridamole and other mechanisms — characterizes ischemic response patterns
6779029	1981	Diagnostic Study	Japanese Circulation Journal	Dipyridamole-loading thallium imaging in 38 CAD patients; diagnostic sensitivity 66%, improved to 87% when combined with exercise stress imaging
8634169	1996	Cohort Study	Portuguese Journal of Cardiology	3-year prognosis assessment of suspected CAD patients with normal dipyridamole-thallium scintigram; favorable outcomes in truly normal scans
2022043	1991	Review	Circulation	Pathophysiological basis for noninvasive coronary stenosis evaluation; discusses coronary steal mechanism underlying dipyridamole stress testing
16630456	2006	Case Series	Zhonghua Xin Xue Guan Bing Za Zhi	Clinical characteristics of typical vs. atypical coronary artery spasm; dipyridamole referenced in the diagnostic workup context
7628141	1995	Case Report	Clinical Nuclear Medicine	Patient with documented variant angina, migraine, and asthma; dipyridamole scintigraphy confirmed inferior/posterior wall ischemia during exercise
6125623	1982	Review	Kardiologiia	Diagnostic and therapeutic challenges in stenocardia including variant angina; reviews role of pharmacological testing agents

Safety Considerations

Key Warnings (derived from literature evidence):

Dipyridamole can precipitate coronary vasospasm in patients with Prinzmetal (variant) angina through the coronary steal phenomenon. This effect is well-documented and forms the clinical basis for dipyridamole stress testing (PMID 3421166).
The 1978 clinical report (PMID 633593) confirms dipyridamole may aggravate rather than suppress variant angina attacks — this is mechanistically consistent with coronary steal.
Aminophylline (an adenosine antagonist) should always be available to reverse dipyridamole-induced vasodilation in clinical settings where this drug is administered.

Please refer to the package insert for complete safety information, including all warnings and contraindications. Philippines TFDA package insert PDF review is recommended as a critical next step (currently a Blocking data gap).

Conclusion and Next Steps

Decision: Hold

Rationale: Dipyridamole’s mechanism — potentiation of coronary vasodilation via adenosine accumulation — is associated with provoking rather than treating Prinzmetal angina. The literature clearly establishes it as a stress test provocateur in this condition, and there are zero clinical trials supporting therapeutic use. Advancing without resolving this safety signal would pose an unacceptable risk to patients.

Important Context — Stronger Evidence Exists for Other Ranked Indications: While rank 1 (Prinzmetal angina) is blocked, the Evidence Pack contains substantially stronger support for stroke disorder (rank 2, 31 clinical trials including completed Phase 3/4 RCTs such as PRoFESS, JASAP, and ESPRIT — qualifying for L1 evidence) and transient ischemic attack (rank 5, 15 trials, multiple Cochrane reviews — also L1). The aspirin + extended-release dipyridamole combination (Aggrenox) is an internationally guideline-endorsed secondary stroke prevention therapy. These indications represent far higher-value repurposing targets for Philippines registration consideration.

To proceed, the following is needed:

Download Philippines TFDA (or reference FDA) package insert PDF to extract official warnings and contraindications (currently a Blocking data gap)
Query DrugBank API to obtain full mechanism of action data (currently a High-severity data gap)
Formally reassign primary repurposing focus to stroke disorder (rank 2) or TIA (rank 5), which have robust international RCT evidence and established clinical guidelines
Assess Philippines regulatory pathway for new indication registration of aspirin + dipyridamole for secondary stroke prevention
Conduct local clinical expert consultation regarding feasibility and unmet need in the Philippines cerebrovascular disease population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.